139 related articles for article (PubMed ID: 3829008)
1. Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide.
Hassan MN; Reches A; Kuhn C; Higgins D; Fahn S
Clin Neuropharmacol; 1986; 9(1):71-8. PubMed ID: 3829008
[TBL] [Abstract][Full Text] [Related]
2. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE
Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255
[TBL] [Abstract][Full Text] [Related]
3. Possible dissociation of central dopamine receptor antagonism and cataleptic behavior.
Hruska RE
Pharmacol Biochem Behav; 1985 Nov; 23(5):789-95. PubMed ID: 4080765
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
Seeger TF; Thal L; Gardner EL
Psychopharmacology (Berl); 1982; 76(2):182-7. PubMed ID: 6805029
[TBL] [Abstract][Full Text] [Related]
6. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
[TBL] [Abstract][Full Text] [Related]
7. Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops.
Kinon BJ; Kane JM
Psychopharmacology (Berl); 1989; 98(4):465-71. PubMed ID: 2505286
[TBL] [Abstract][Full Text] [Related]
8. Lack of potency of metoclopramide's metabolites in various dopaminergic models.
Stanley M; Wazer D; Virgilio J; Kuhn CM; Benson DI; Meyerson LR
Pharmacol Biochem Behav; 1983 Feb; 18(2):263-6. PubMed ID: 6682229
[TBL] [Abstract][Full Text] [Related]
9. The effects of chronic lithium on behavioral and biochemical indices of dopamine receptor supersensitivity in the rat.
Pittman KJ; Jakubovic A; Fibiger HC
Psychopharmacology (Berl); 1984; 82(4):371-7. PubMed ID: 6427831
[TBL] [Abstract][Full Text] [Related]
10. Effects of dextromethorphan on dopamine dependent behaviours in rats.
Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
[TBL] [Abstract][Full Text] [Related]
11. Chronic autoreceptor blockade and neuroleptic-induced dopamine receptor hypersensitivity.
Gordon JH; Clopton JK; Curtin JC; Koller WC
Pharmacol Biochem Behav; 1987 Feb; 26(2):223-8. PubMed ID: 3575347
[TBL] [Abstract][Full Text] [Related]
12. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
[TBL] [Abstract][Full Text] [Related]
13. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
Lynch MR
Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
[TBL] [Abstract][Full Text] [Related]
14. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Hamblin MW; Creese I
Life Sci; 1983 May; 32(19):2247-55. PubMed ID: 6133202
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and dopaminergic activity of 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide.
Crider AM; Hemdi TF; Hassan MN; Fahn S
J Pharm Sci; 1984 Nov; 73(11):1585-7. PubMed ID: 6549185
[TBL] [Abstract][Full Text] [Related]
16. A dietary haloperidol regimen for inducing dopamine receptor supersensitivity in rats.
Frey JM; Morgan WW; Ticku MK; Huffman RD
Pharmacol Biochem Behav; 1987 Apr; 26(4):661-9. PubMed ID: 3602028
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.
Rupniak NM; Mann S; Hall MD; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
Psychopharmacology (Berl); 1984; 84(4):503-11. PubMed ID: 6441951
[TBL] [Abstract][Full Text] [Related]
18. Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK&F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide.
Molloy AG; Waddington JL
Eur J Pharmacol; 1985 Feb; 108(3):305-8. PubMed ID: 3886407
[TBL] [Abstract][Full Text] [Related]
19. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
Jenner P; Rupniak NM; Hall MD; Dyer R; Leigh N; Marsden CD
Eur J Pharmacol; 1981 Nov; 76(1):31-6. PubMed ID: 6119220
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
